Provoked venous thromboembolism (VTE) refers to a deep vein thrombosis or pulmonary embolism that occurs in the setting of an identifiable clinical risk factor, either transient or persistent.
This distinction from unprovoked VTE is central to estimating recurrence risk and determining anticoagulation duration.
Provoked VTE is usually defined as VTE associated with at least one acquired risk factor present around the time of the event:
Major surgery or trauma, especially orthopedic or abdominal procedures. Prolonged immobilization (casting, bed rest, long-haul travel in high‑risk patients). Pregnancy, postpartum period, and estrogen-containing contraception or hormone therapy. Active cancer and cancer therapy. Chronic medical conditions causing immobility or venous stasis, and some chronic inflammatory states.
Provoked VTE can be further classified:
Major transient risk factor: e.g., surgery with general anesthesia >30 minutes, major trauma, hospitalization with bed confinement ≥3 days.
Minor transient risk factor: surgery.
The first VTE provoked by a major transient risk factor has a substantially lower recurrence risk than unprovoked events once anticoagulation is stopped.
The recurrence risk after surgery-provoked VTE is particularly low, whereas VTE provoked by nonsurgical transient factors has a recurrence risk intermediate between surgery-provoked and unprovoked events.
Patients with provoked DVT or PE generally have fewer recurrent VTE episodes than those with unprovoked disease, although cancer-associated thrombosis is an important exception with high recurrence despite being considered provoked.
An unprovoked VTE carries roughly 2–3 times the recurrence risk of VTE provoked by transient factors and several-fold higher risk than surgery-provoked VTE.
For a first provoked VTE due to a major transient risk factor such as a major surgery;major trauma, guideline-based practice typically favors a finite treatment course, often about 3 months, assuming bleeding risk and clinical course are uncomplicated.
For provoked VTE due to persistent factors such as active cancer, longer or indefinite anticoagulation is often recommended or considered while the provoking condition persists, balancing bleeding and recurrence risks.
When additional chronic or minimally provoking factors coexist-obesity, minor immobility, low-dose estrogen, recurrence risk can approach that of unprovoked VTE, and many experts individualize decisions about extended anticoagulation in this group.
For an individual patient with provoked VTE, key management questions include: identifying and addressing the provoking factor, deciding on length and intensity of anticoagulation, and reassessing recurrence and bleeding risks if additional chronic risk factors are present.